Table 1.

Microbiota-based Therapies in Development for IBD

Therapy Type	Company	Location	Product*	Delivery*	Development Stage	Mechanism
Ecology modulator	Enterome	USA	EB-8018 small molecule	oral	phase 2 study of patients with CD	prevents pathobiont invasion by blocking FIMH
	Immuron	Australia	N/A	oral	preclinical	antibodies and adjuvant to boost immune response to pathobionts
	BiomX	Israel	BX002	N/A	preclinical	bacteriophage to deplete pathobionts
	Eligo	France	N/A	N/A	preclinical	Crispr-CAS to deplete pathobionts
	Intralytix	USA	EcoActive	oral	phase 1 and 2a study of patients with CD	bacteriophage to target AIEC
	Artizan Biosciences	USA	N/A	N/A	Preclinical	Subtractive therapy
Live Biotherapeutic Product	Seres Therapeutics	USA	SER287 naturally derived community	oral	phase 2 study of patients with UC	not available
	Seres Therapeutics Janssen (Vendanta License)	USA	SER301 defined community	oral	preclinical	not available
			VE202 defined community	oral	phase 1 study of patients with UC	Induce Treg cells
	Rebiotix (acquired by Ferring)	USA	RBX2660	enema	phase 1 in pediatric patients with UC	Restore microbiome composition
	4D Pharma	UK	Thetanix B thetaiotamicron	oral	phase 1 study of patients with CD	not available
	4D Pharma Osel	UK	Rosburix R hominis	oral	preclinical	not available
		USA	CBM588 C butyricum	oral	phase 1	Increase SCFAs
	ImmuneBiotech	Sweden	IB002 Lactobacilli	N/A	preclinical	not available
	Actobiotic	USA	AG-014 GMO	oral	phase 1	heterologous expression of anti-TNF nanobody by Lactobacillus
	Rise Therapeutics	USA	R-3750 GMO	N/A	preclinical	Lactobacillus for heterologous expression
	Nordisk Rebalance	Denmark	Profermin L latarum oats phosphatidylcholine	oral	marketed as food for special medical purpose	phase 2 of patients with UC, a prebiotic that increases SCFAs
	Finch Therapeutics	USA	FIN524, defined community	oral	preclinical studies of colitis	not available
	Allergan	Ireland	ABI-M201,301	oral	preclinical	licensed from Assembly Biosciences and uses Gemicel coating
	NextBiotix/Exeliom Biosciences	FRA	NBX-1650	n/a	Preclinical	F. prausnitzii to treat inflammation
	ViThera	USA	VT301	Oral	Preclinical	Modified Lactobacilli strains
	Chain Biotech	USA	CHN-1, CHN-2	Oral	preclinical	anti-microbial peptide with Clostridium Assisted Drug Delivery
	PanTheryx	USA	PTX-400	Oral	Preclinical	Medical food - prebiotic
Microbial effectors	Host Therabiomics	UK/USA	L1173	N/A	preclinical	platform to identify effectors
	Second Genome	USA	SG-2–0776 protein	oral	preclinical	intestinal healing
	Symbiotix Biotherapies	USA	SYMB-104 polysaccharide A	N/A	preclinical	B fragilis-derived immune modulator
	Alma Bio Therapeutics	FRA	N/A Plasmid	Injection	Preclinical	Plasmids that produce Heat Shock Proteins
	Enterome	USA	EB110/EB220	oral	preclinical	microbial metabolite associated with CD
Formulation	Finch Therapeutics	USA	aquashell	oral	N/A	pH release polysaccharide
	Intract Pharma	UK	phloral duocoat	oral	N/A	pH release
	Prodigest	Belgium	in vitro microbiome model	N/A	N/A	predict in vivo conditions
	Synlogic	USA	genetically modified organism	N/A	N/A	Not available
	Assembly	USA	gemicel capsule	oral	N/A	pH release
Host Target	Second Genome	USA	SGM-1019 Small molecule	oral	phase 1	modulates inflammasome

N/A, not applicable because agent is in preclinical stage of development

Note: Companies were identified by the Janssen Human Microbiome Institute from public resources.